Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Bulk RNA seq profile of CD8+ T cells in peripheral blood lymphocytes from 28 melanoma patients

ABSTRACT: Bulk RNA seq profile of CD8+ T cells in peripheral blood lymphocytes from 28 melanoma patients

PROVIDER: PRJNA720122 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR14154400_1.fastq.gz	Fastqsanger.gz
	SRR14154400_2.fastq.gz	Fastqsanger.gz
	SRR14154401_1.fastq.gz	Fastqsanger.gz
	SRR14154401_2.fastq.gz	Fastqsanger.gz
	SRR14154402_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 112

Similar Datasets

Bulk RNA seq profile of CD8+ T cells in peripheral blood lymphocytes from 28 melanoma patients

Project description:CD8+ T cells are the primary target of immune checkpoint inhibitor (ICI) therapy in the treatment of cancers. ICI therapy only benefits a subset of patients and complicating this issue is a reliable prediction method that does not require invasive biopsies. We built an ICI response prediction model using scRNA seq data, and for validation of the model here we profiled transcriptome of CD8+ T cells in peripheral blood lymphocytes of 28 melanoma patients that responded to ICI or not using bulk RNA sequencing.

2021-11-16 | GSE171256 | GEO

CD8+ T cells in peripheral blood lymphocytes and tumor-infiltrating lymphocytes of melanoma patients

Project description:CD8+ T cells are the primary target of immune checkpoint inhibitor (ICI) therapy in the treatment of melanoma. ICI therapy only benefits a subset of patients and complicating this issue is a reliable prediction method that does not require invasive biopsies. In the hope of remedying this challenge, we conducted single-cell transcriptomic analyses of CD8+ T cells in peripheral blood lymphocytes (CD8-mPBLs) and, importantly, tumor-infiltrating lymphocytes (CD8-mTILs) from 8 patients with metastatic melanoma.

2021-11-16 | GSE138720 | GEO

CD8+ T cells in peripheral blood lymphocytes and tumor-infiltrating lymphocytes of melanoma patients

Project description:CD8+ T cells in peripheral blood lymphocytes and tumor-infiltrating lymphocytes of melanoma patients

| PRJNA576899 | ENA

CD8+ T cells in peripheral blood lymphocytes and tumor-infiltrating lymphocytes of melanoma patients: additional validation data

Project description:CD8+ T cells are the primary target of immune checkpoint inhibitor (ICI) therapy in the treatment of cancers. ICI therapy only benefits a subset of patients and complicating this issue is a reliable prediction method that does not require invasive biopsies. We built an ICI response prediction model using scRNA seq data, and for validation of the model here we conduct single cell RNA sequencing of CD8+ T cells in peripheral blood or tumor lymphocytes of 2 additional melanoma patients.

2021-11-16 | GSE153098 | GEO

CD8+ T cells in peripheral blood lymphocytes and tumor-infiltrating lymphocytes of melanoma patients: additional validation data

Project description:CD8+ T cells in peripheral blood lymphocytes and tumor-infiltrating lymphocytes of melanoma patients: additional validation data

| PRJNA641423 | ENA

RNA seq data of CD8+ T cells in peripheral blood lymphocytes from melanoma and lung cancer patients

Project description:CD8+ T cells are the primary target of immune checkpoint inhibitor (ICI) therapy in the treatment of cancers. ICI therapy only benefits a subset of patients and complicating this issue is a reliable prediction method that does not require invasive biopsies. We built an ICI response prediction model using scRNA seq data, and for validation of the model here we profiled transcriptome of CD8+ T cells in peripheral blood lymphocytes of 4 melanoma and 4 lung cancer patients that responded to ICI or not using RNA sequencing.

2021-11-17 | GSE152590 | GEO

Expression data from FACS-sorted CD8+BTLA+ vs CD8+BTLA- Human Tumor-infiltrating Lymphocytes in Metastatic Melanoma

Project description:Adoptive T-cell Therapy (ACT) involves using tumor-infiltrating lymphocytes (TIL) isolated from metastatic melanoma and expanding them ex vivo prior to infusion into lympho-depleted patients. This is one of the most promising approaches to treat metastatic melanoma, with the rates of clinical response between 48-50% based on studies done at NCI, M.D. Anderson Cancer Center (Houston, TX), and Sheba Medical Center (Tel Aviv, Israel). In the Phase II ACT Trial at M.D. Anderson Cancer Center , our group has uncovered an association between positive clinical response and the amount of CD8+ tumor-infiltrating lymphocytes expressing B and T Lymphocyte Attenuator (BTLA), a reported inhibitory receptor on T-cells. We used microarrays to detail the differences in the global programme of gene expression between CD8+BTLA+ vs CD8+BTLA- TILs in order to understand the molecular basis of the clinical association. TILs were isolated by enzymatically digest the melanoma tumor fragments obtained from Stage IIIc/IV melanoma patients at M.D. Anderson Cancer Center. The TILs were expanded with high-dose IL-2 for two weeks prior to sorting by FACS (fluoresecence-activated cell sorter) for CD8+BTLA+ and CD8+BTLA- susbets. RNA was extracted from each sorted subsets and hybridized on Affymetrix microarrays

2013-01-03 | E-GEOD-43260 | biostudies-arrayexpress

RNA seq data of CD8+ T cells in peripheral blood lymphocytes from melanoma and lung cancer patients

Project description:RNA seq data of CD8+ T cells in peripheral blood lymphocytes from melanoma and lung cancer patients

| PRJNA639802 | ENA

RNASeq of PD-1loCTLA-4lo versus PD-1hiCTLA-4hi CD8 tumor-infiltrating lymphocytes from human melanoma

Project description:The aim of the study is to analyze and compare the transcriptional profiles of PD-1loCTLA-4lo versus PD-1hiCTLA-4hi CD8 tumor-infiltrating lymphocytes from human melanoma

2020-03-28 | GSE147620 | GEO

Expression data from FACS-sorted CD8+BTLA+ vs CD8+BTLA- Human Tumor-infiltrating Lymphocytes in Metastatic Melanoma

2013-01-03 | GSE43260 | GEO